Select therapeutic use:
Indications for BYDUREON:
Adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes.
Limitations Of use:
Not recommended as first-line therapy for patients inadequately controlled on diet and exercise. Not a substitute for insulin. Not for treating type 1 diabetes or diabetic ketoacidosis. Not studied in combination with insulin or with history of pancreatitis.
Give by SC inj in abdomen, thigh, or upper arm. Inject immediately after mixing. 2mg once every 7 days (weekly). Changing from Byetta: discontinue, then start Bydureon.
History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.
Risk of thyroid C-cell tumors possible; monitor. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. Severe GI disorders, renal impairment (CrCl <30mL/min), end-stage renal disease: not recommended. Renal transplantation. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need lower dose of these. May delay absorption of oral drugs. Monitor warfarin.
Glucagon-like peptide-1 (GLP-1) receptor agonist.
Nausea, diarrhea, headache, vomiting, constipation, dyspepsia, inj site reactions; possible antibody formation (glycemic response may be attenuated), pancreatitis (may be fatal), hypersensitivity reactions.
Single-dose trays—4 (each contains 1 vial, 1 prefilled syringe with diluent, vial connector and custom needles); Single-dose pens—4 (each contains 1 Bydureon Pen and 1 custom needle)